Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Sanofi India Ltd - 500674 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

 Pursuant to our letter dated 3rd November 2022, we wish to inform you that the Company is seeking approval of Members of the Company through an Ordinary Resolution for appointment of Ms. Annapurna Das as Non-Executive (Non-Independent) Director of the Company with effect from 3rd November 2022, through Ordinary Resolution, as set out in the Postal Ballot notice dated 3rd November 2022, by way of electronic voting ('remote e-voting').
25-11-2022
Bigul

Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate
18-11-2022
Bigul

Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate.
14-11-2022

Sanofi India Standalone September 2022 Net Sales at Rs 691.90 crore, down 8.3% Y-o-Y

 NULL
09-11-2022

Hold Sanofi India; target of Rs 6385: ICICI Direct

 ICICI Direct recommended hold rating on Sanofi India with a target price of Rs 6385 in its research report dated November 04, 2022.
07-11-2022

Sanofi India posts Rs 131 cr profit in Sept quarter, revenue at Rs 692 cr

 Drug firm Sanofi India on Thursday reported a net profit of Rs 131 crore for the third quarter ended September 2022. The company had posted a net profit of Rs 530 crore in the July-September quarter of last year, the company said in a regulatory filing. The drug firm follows a January-December financial year. Revenue from operations stood at Rs 692 crore in the period under review. The same stood at Rs 754 crore in the corresponding period previous year. The company said the results of the September quarter were not comparable with the same quarter last year as it had transferred its nutraceuticals business to Universal Nutriscience, enabling a gain of Rs 489 crore.
03-11-2022
Bigul

Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Pursuant to the requirements of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the the Board of Directors at its meeting held today i.e., 3rd November 2022 noted the resignation of Mr. Charles Billard and based on the recommendation of the Nomination and Remuneration Committee, approved the appointment of Ms. Annapurna Das (DlN: 08634664) as an Additional and Non-Executive (Non-Independent) Director of the Company with effect from 3rd November 2022. The said appointment will be subject to the approval of the Members of the Company through Postal Ballot.
03-11-2022
Bigul

Sanofi India Ltd - 500674 - Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Quarter And Nine Months Ended On 30Th September, 2022

 We refer to our letter dated 21st October 2022, informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 02.00 p.m. and concluded at 5.00 p.m. The Board approved Unaudited Financial Results for the quarter and nine months ended 30th September 2022. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the Unaudited Financial Results for the quarter and nine months ended 30th September 2022 approved at this Meeting with a copy of the Limited Review Report duly signed by the Auditors of the Company.
03-11-2022
Bigul

Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s)
21-10-2022
Bigul

Sanofi India Ltd - 500674 - Board Meeting Intimation for Meeting Of Board Of Directors To Be Held On 3Rd November 2022

 Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company will be held on Thursday, 3rd November 2022; inter alia to consider the unaudited financial results for the quarter and nine months ended 30th September 2022. Further, to our intimation on 30th September 2022, this is to inform you that as per the "Sanofi India Limited - Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons, the trading window of the Company, which was closed from 1st October 2022, for publication of financial results of the Company for the quarter and nine months ended 30th September 2022 shall remain closed up to Saturday, 5th November 2022 (inclusive of both days).
21-10-2022
Next Page
Close

Let's Open Free Demat Account